Upstream Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
UPB Nasdaq 2836 upstreambio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Upstream Bio, Inc.

First subject dosed in Upstream Bio’s Phase II trial of verekitug for COPD - Jul 9th, 2025 7:00 am
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) - Jul 8th, 2025 5:00 am
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - Jun 15th, 2025 5:45 am
Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 - Jun 5th, 2025 5:00 am
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Jun 4th, 2025 5:00 am
Upstream Bio Appoints Stacy Price as Chief Technology Officer - May 20th, 2025 5:00 am
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs - May 6th, 2025 5:00 am
Upstream Bio (NASDAQ:UPB) Is In A Good Position To Deliver On Growth Plans - Apr 11th, 2025 5:52 am
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - Mar 12th, 2025 5:00 am
Upstream Bio to Present at Upcoming March Investor Conferences - Feb 25th, 2025 6:00 am
Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps - Feb 11th, 2025 7:00 am
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 6th, 2025 6:00 am
Upstream Bio Appoints Allison Ambrose as General Counsel - Dec 17th, 2024 6:00 am
Upstream Bio Announces Addition to Russell 2000® Index - Dec 16th, 2024 6:00 am
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference - Nov 21st, 2024 6:00 am
Upstream Bio reports Q3 revenue $607,000 vs $621,000 last year - Nov 8th, 2024 5:11 am
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Nov 7th, 2024 5:00 am
Orbimed Advisors LLC Acquires New Stake in Upstream Bio Inc - Oct 17th, 2024 5:02 pm
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Oct 15th, 2024 2:15 pm
Opening Day: Another trio of biotech IPOs make Friday debut - Oct 14th, 2024 4:45 am